KEZAR LIFE SCIENCES, INC. 4000 Shoreline Court, Suite 300 South San Francisco, CA 94080

July 9, 2019

Via EDGAR

U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549

Attn: Donald Field

Re: Kezar Life Sciences, Inc.

Registration Statement on Form S-3

File No. 333-232542

Acceleration Request

Requested Date: Thursday, July 11, 2019

Requested Time: 4:00 P.M. Eastern Daylight Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the "*Registrant*") hereby requests that the Securities and Exchange Commission (the "*Commission*") take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-232542) (the "*Registration Statement*") to become effective on Thursday, July 11, 2019, at 4:00 p.m. Eastern Daylight Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the "*Staff*"). This request for acceleration is subject, however, to your receiving a telephone call prior to such time from Cooley LLP, counsel to the Registrant, confirming this request. The Registrant hereby authorizes each of Laura Berezin or Jaime Chase of Cooley LLP to make such request on its behalf.

[Signature page follows]

cc: John Fowler, Kezar Life Sciences, Inc. Laura Berezin, Cooley LLP Jaime Chase, Cooley LLP Robert Phillips, Cooley LLP Very truly yours,

Kezar Life Sciences, Inc.

By: /s/ Marc Belsky

Marc Belsky Chief Financial Officer